TY - JOUR
T1 - Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy
AU - Ennishi, D.
AU - Yokoyama, M.
AU - Terui, Y.
AU - Asai, H.
AU - Sakajiri, S.
AU - Mishima, Y.
AU - Takahashi, S.
AU - Komatsu, H.
AU - Ikeda, K.
AU - Takeuchi, K.
AU - Tanimoto, Mitsune
AU - Hatake, Kiyohiko
PY - 2009
Y1 - 2009
N2 - Background: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. However, its prognostic value has not been well known since the introduction of rituximab. Patients and methods: We retrospectively evaluated the prognostic impact of SIL-2R in 228 DLBCL patients, comparing 141 rituximab-combined CHOP (RCHOP)-treated patients with 87 CHOP-treated patients as a historical control. Results: Patients with high serum SIL-2R showed significantly poorer event-free survival (EFS) and overall survival (OS) than patients with low SIL-2R in both the RCHOP group (2-year EFS, 66% versus 92%, P < 0.001; OS, 82% versus 95%, P = 0.005) and the CHOP group (2-year EFS, 40% versus 82%; OS, 61% versus 90%, both P < 0.001). Multivariate analysis including the five parameters of International Prognostic Index (IPI) and two-categorized IPI revealed that SIL-2R was an independent prognostic factor for EFS and OS in the RCHOP group as well as in the CHOP group. Conclusions: Our results demonstrate that SIL-2R retains its prognostic value in the rituximab era. The prognostic value of SIL-2R in DLBCL patients receiving rituximab-combined chemotherapy should be reassessed on a larger scale and by long-term follow-up.
AB - Background: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. However, its prognostic value has not been well known since the introduction of rituximab. Patients and methods: We retrospectively evaluated the prognostic impact of SIL-2R in 228 DLBCL patients, comparing 141 rituximab-combined CHOP (RCHOP)-treated patients with 87 CHOP-treated patients as a historical control. Results: Patients with high serum SIL-2R showed significantly poorer event-free survival (EFS) and overall survival (OS) than patients with low SIL-2R in both the RCHOP group (2-year EFS, 66% versus 92%, P < 0.001; OS, 82% versus 95%, P = 0.005) and the CHOP group (2-year EFS, 40% versus 82%; OS, 61% versus 90%, both P < 0.001). Multivariate analysis including the five parameters of International Prognostic Index (IPI) and two-categorized IPI revealed that SIL-2R was an independent prognostic factor for EFS and OS in the RCHOP group as well as in the CHOP group. Conclusions: Our results demonstrate that SIL-2R retains its prognostic value in the rituximab era. The prognostic value of SIL-2R in DLBCL patients receiving rituximab-combined chemotherapy should be reassessed on a larger scale and by long-term follow-up.
KW - Diffuse large B-cell lymphoma
KW - Rituximab
KW - Soluble interleukin-2 receptor
UR - http://www.scopus.com/inward/record.url?scp=61649088127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61649088127&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdn677
DO - 10.1093/annonc/mdn677
M3 - Article
C2 - 19074749
AN - SCOPUS:61649088127
SN - 0923-7534
VL - 20
SP - 526
EP - 533
JO - Annals of Oncology
JF - Annals of Oncology
IS - 3
ER -